- Home
- DYN vs CPRI Comparison
DYN vs CPRI Comparison
Compare DYN & CPRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DYN
- CPRI
- Stock Information
- Founded
- DYN 1984
- CPRI 1981
- Country
- DYN United States
- CPRI United Kingdom
- Employees
- DYN N/A
- CPRI N/A
- Industry
- DYN Medicinal Chemicals and Botanical Products
- CPRI Apparel
- Sector
- DYN Health Care
- CPRI Consumer Discretionary
- Exchange
- DYN Nasdaq
- CPRI Nasdaq
- Market Cap
- DYN 1.9B
- CPRI 2.2B
- IPO Year
- DYN 2020
- CPRI 2011
- Fundamental
- Price
- DYN $22.58
- CPRI $20.75
- Analyst Decision
- DYN Strong Buy
- CPRI Buy
- Analyst Count
- DYN 14
- CPRI 12
- Target Price
- DYN $34.93
- CPRI $24.08
- AVG Volume (30 Days)
- DYN 3.0M
- CPRI 2.1M
- Earning Date
- DYN 10-28-2025
- CPRI 11-04-2025
- Dividend Yield
- DYN N/A
- CPRI N/A
- EPS Growth
- DYN N/A
- CPRI N/A
- EPS
- DYN N/A
- CPRI N/A
- Revenue
- DYN N/A
- CPRI $4,391,000,000.00
- Revenue This Year
- DYN N/A
- CPRI N/A
- Revenue Next Year
- DYN N/A
- CPRI $3.83
- P/E Ratio
- DYN N/A
- CPRI N/A
- Revenue Growth
- DYN N/A
- CPRI N/A
- 52 Week Low
- DYN $6.36
- CPRI $11.86
- 52 Week High
- DYN $35.68
- CPRI $26.23
- Technical
- Relative Strength Index (RSI)
- DYN 74.06
- CPRI 45.98
- Support Level
- DYN $23.05
- CPRI $22.27
- Resistance Level
- DYN $25.00
- CPRI $22.98
- Average True Range (ATR)
- DYN 1.02
- CPRI 0.71
- MACD
- DYN 0.72
- CPRI -0.08
- Stochastic Oscillator
- DYN 78.24
- CPRI 37.71
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
About CPRI Capri Holdings Limited
Capri Holdings is a marketer, distributor, and retailer of upscale accessories and apparel in the Americas, Europe, and Asia. Michael Kors, Capri's original and largest brand by sales, offers handbags, footwear, and apparel through more than 700 company-owned stores, wholesale, and e-commerce. Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. Its products are sold in more than 200 company-operated stores. Capri also owns a third brand, Versace, but has agreed to sell it to Prada. John Idol has served as Capri's CEO since 2003.